Seattle Biotech Company Dendreon Files For Bankruptcy
Ross Reynolds talks to Seattle biotech writer Luke Timmerman about the biotech company Dendreon, which filed for bankruptcy after their prostate cancer drug failed to make a sizable profit.
You make this possible. Support our independent, nonprofit newsroom today.
Give NowRoss Reynolds talks to Seattle biotech writer Luke Timmerman about the biotech company Dendreon, which filed for bankruptcy after their prostate cancer drug failed to make a sizable profit.
